Clinical trial · Interventional
DPTX3186 in Wnt Pathway Activated Solid Tumors
An Open Label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt Pathway Activated Solid Tumors Where No Other Treatments Exist
NCT07312903CI-TRIAL-00100597recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DPTX3186 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dose Escalation
- interventionNames
- Drug: DPTX3186
Primary outcomes (1)
- measure
- Incidence of treatment emergent adverse events and serious adverse events.
- timeFrame
- Up to 36 Months
- description
- 1. Outcome Measure: Incidence of Treatment Emergent Adverse-Events Measure Description: Number of subjects with treatment-emergent adverse events (TEAEs) Time Frame: up to 36 months 2. Outcome Measure: Incidence of Serious Adverse Events Measure Description: Number of subjects with serious adverse events (SAEs) Time Frame: up to 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available. * At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI. * ECOG performance status of 0 or 1. * Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy. * Age ≥18 years (or ≥ age of majority per local regulation) * Life expectancy ≥3 months * Willing and able to comply with protocol requirements Exclusion Criteria: * Symptomatic or uncontrolled brain metastasis requiring concurrent treatment, * Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.). * Inadequate organ function * Known hypersensitivity to study drug or excipients
References
Publications (0)
Data not yet available
No reference posted for this study.